These are the stocks posting the largest moves before the bell.Market Insiderread more
Morgan Stanley caused a stir with its "bear case" scenario of $10. Now, Citi is getting in on the act.Investingread more
Qualcomm unlawfully suppressed competition in the market for cellphone chips and used its dominant position to impose excessive licensing fees, a U.S. judged ruled.Technologyread more
Target's e-commerce sales also surged 42%, as shoppers increasingly turned to its curbside pickup service for online orders, something Amazon can't offer.Retailread more
Homeowners are taking advantage of lower interest rates, rushing to refinance their mortgages before rates potentially turn higher again.Real Estateread more
Department stores are being hung out to dry as Kohl's shares fall after earnings, but some experts still see opportunity in the space.Trading Nationread more
Lowe's shares plummeted 8% before the bell Wednesday after the company posted mixed fiscal first-quarter results and cut its forecast for the year, as higher costs weighed on...Retailread more
It may be years from visiting your neighborhood, but a walking robot is part of Ford's vision for how its autonomous vehicles will deliver packages.Autosread more
Brazilian makeup brand Natura Cosmeticos agreed to buy Avon Products, according to two media reports early on Wednesday.Retailread more
Consumers in China are taking to social media to express their support for Huawei as the U.S. government looks to ramp up pressure on the Chinese smartphone maker.Technologyread more
Tensions between the two parties have heightened in recent months as the campaign for seats in the Brussels and Strasbourg-based parliament has crescendoed.Europe Politicsread more
In fact, Cramer has been in a heated love affair with biotech for more than 30 years. While you don't get a rally from them every day, he thinks they are more reliable than any other group.
"Never stop loving biotech. That's been my mantra since the 1980s, and every day I thank my lucky stars that I haven't abandoned the concept or the stocks," the "Mad Money" host said.
Tuesday was one of those days that served as a reminder that the love is still in the air. Especially when Biogen Idec's stock soared on a positive Alzheimer's study that has improved cognition significantly in just 54 weeks, taking the drug right into Phase 3 testing.
This company was one of the first stocks the "Mad Money" host bought when Genentech, Amgen and Biogen basically invented the biotech genre.
"When one of these stocks flies, the whole group tends to fly, in part because they are tightly correlated by moronic ETF's that take up the good with the bad. Fortunately, there are enough goods in the basket to overwhelm the bad."
That is why Cramer never minds when Regeneron and Celgene move up with whatever flavor of the day news is released. Though many think that these stocks are one-trick ponies, the reality is that they always seem to have something up their sleeves.
Regeneron is pumping out new formulations constantly, especially for cholesterol and asthma. Celgene is a breeding ground for treatments for psoriatic arthritis and cancers. It also has a stake in one of Cramer's faves, Agios Pharma, which is testing a formula to kill cancer cells without infusing the entire body with toxins.
Though Agios has had a huge run with gobs of profit taking, and it may already be late in the game, Cramer wouldn't be surprised if Celgene buys the 85 percent of Agios that it doesn't already own.
Another reminder of biotech love seen on Tuesday was a 12 percent gain for Avanir Pharmaceuticals on news that Japanese company Otsuka agreed to buy it for $3.5 billion. And that's a cherry on top of the 400 percent gain Avanir already clocked, year-to-date.
Read more from Mad Money with Jim Cramer
Cramer Remix: What falling oil means to you
Cramer talks crude chaos with CEO
Cramer's worst case oil scenarios
"In an era when you are buffeted by cyclical headwinds … it's comforting to know that you can own a biotech and get hit with the kind of lightning that can make your year," Cramer said.
It won't happen every day, but the love shows up more often than most other angry cohorts, which is why Cramer thinks you should love biotech, too.